Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Top Cited Papers
- 3 May 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (18) , 1809-1822
- https://doi.org/10.1056/nejmoa067312
Abstract
A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)Keywords
This publication has 33 references indexed in Scilit:
- Alendronate and Atrial FibrillationNew England Journal of Medicine, 2007
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnnals of the Rheumatic Diseases, 2006
- Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With CancerJournal of Oncology Practice, 2006
- Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE StudyJournal of Bone and Mineral Research, 2005
- Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurrent Medical Research and Opinion, 2005
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Defining Incident Vertebral Deformity: A Prospective Comparison of Several ApproachesJournal of Bone and Mineral Research, 1999
- Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fracturesJournal of Bone and Mineral Research, 1995
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993